Zhou Lin, Hao Zhipeng, Huang Kun, Chen Yuchen, Zhang Ni, Fu Xiangning, Li Yangkai
Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
JTCVS Tech. 2025 Mar 8;31:169-176. doi: 10.1016/j.xjtc.2025.01.029. eCollection 2025 Jun.
Radical surgery for T4 non-small cell lung cancer, especially for those tumors invading the heart, poses a significant challenge for thoracic surgeons, as demonstrated by the paucity of previous reports. This study aimed to report our surgical technique and experience with this radical surgery that necessitated cardiopulmonary bypass and to assess the prognosis of these patients with locally advanced non-small cell lung cancer.
This study included 4 patients with non-small cell lung cancer (enrolled between 2010 and 2020) who underwent en bloc tumor resection and reconstruction of the left atrium with cardiopulmonary bypass. The clinical features, preoperative assessment, surgical technique, and outcomes of these patients were reviewed.
All patients received complete R0 resection and reconstruction. The mean operative and cardiopulmonary bypass times were 370.5 ± 100.7 minutes and 20.3 ± 13.8 minutes, respectively. One patient died within 30 days after surgery, 2 patients died 46 days and 7 months postoperatively, and 1 patient is still alive 47 months postoperatively without recurrence or metastasis.
In the contemporary era of targeted and immunotherapy, surgical intervention may offer a viable alternative for patients with T4 NSCLC involving the left atrium who have exhibited resistance to neoadjuvant therapeutic regimens.
T4期非小细胞肺癌的根治性手术,尤其是对于那些侵犯心脏的肿瘤,对胸外科医生构成了重大挑战,以往报告的匮乏就证明了这一点。本研究旨在报告我们进行这种需要体外循环的根治性手术的技术和经验,并评估这些局部晚期非小细胞肺癌患者的预后。
本研究纳入了4例非小细胞肺癌患者(2010年至2020年期间入组),他们接受了肿瘤整块切除及体外循环下左心房重建。回顾了这些患者的临床特征、术前评估、手术技术和结果。
所有患者均接受了R0根治性切除及重建。平均手术时间和体外循环时间分别为370.5±100.7分钟和20.3±13.8分钟。1例患者术后30天内死亡,2例患者分别在术后46天和7个月死亡,1例患者术后47个月仍存活,无复发或转移。
在当代靶向治疗和免疫治疗时代,对于对新辅助治疗方案耐药的累及左心房的T4期非小细胞肺癌患者,手术干预可能是一种可行的选择。